<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801411</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000624374</org_study_id>
    <secondary_id>SINGAPORE-NCC0705</secondary_id>
    <secondary_id>SANOFI-AVENTIS-NCC0705</secondary_id>
    <nct_id>NCT00801411</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>A Randomised Phase 2 Study of Neoadjuvant Docetaxel and Cyclophosphamide Compared to Doxorubicin and Cyclophosphamide in Operable Node Negative Breast Cancer With Normal Topoisomerase IIα Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, docetaxel, and doxorubicin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving combination chemotherapy before surgery may make the&#xD;
      tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet&#xD;
      known which chemotherapy regimen is more effective in treating breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying cyclophosphamide given together with&#xD;
      docetaxel to see how well it works compared with cyclophosphamide given together with&#xD;
      doxorubicin in treating women with newly diagnosed breast cancer that can be removed by&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate tumor pathological complete response rate after neoadjuvant cyclophosphamide&#xD;
           in combination with docetaxel vs doxorubicin hydrochloride in women with operable&#xD;
           clinically node-negative breast cancer and normal topoisomerase IIα expression.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess tumor clinical and pathological overall response rates in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  To assess the safety and toxicity of these regimens.&#xD;
&#xD;
        -  To assess disease-free survival and overall survival of these patients.&#xD;
&#xD;
        -  To assess the efficacy of short-course (3 days) filgrastim (G-CSF) as primary and&#xD;
           secondary prophylaxis against febrile neutropenia in patients receiving docetaxel and&#xD;
           cyclophosphamide.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients are stratified according to hormone receptor status (estrogen receptor [ER]- or&#xD;
      progesterone receptor [PR]-positive vs ER- and PR-negative) and T stage (T2 vs T3). Patients&#xD;
      are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.&#xD;
&#xD;
      In both arms, treatment repeats every 21 days for 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. After completion of neoadjuvant chemotherapy, all&#xD;
      patients undergo surgery.&#xD;
&#xD;
      Tumor specimens obtained prior to neoadjuvant chemotherapy are analyzed for topoisomerase IIα&#xD;
      gene and protein expression by IHC and FISH. Tissue samples are also collected at surgery for&#xD;
      future studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 2 years, every 6&#xD;
      months for 3 years, and then annually for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and pathological overall response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Operable disease&#xD;
&#xD;
          -  Must have clinical T2 (&gt; 2cm) or T3 (&gt; 5 cm) primary tumors with no clinical lymph&#xD;
             node involvement (N0)&#xD;
&#xD;
               -  No clinical T4 lesion (e.g., peau d'orange, skin ulceration, satellite nodules,&#xD;
                  or inflammatory breast cancer)&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
          -  Known hormone receptor status&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 (Karnofsky PS 60-100%)&#xD;
&#xD;
          -  Life expectancy &gt; 10 years&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/mm³&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal or creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Normal cardiac ejection fraction, defined as ≥ 50% by MUGA scan or 2D-ECHO&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to docetaxel or other agents used in this study&#xD;
&#xD;
          -  No history of pre-existing peripheral neuropathy&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No prior malignancies except curatively treated basal cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies with the intent&#xD;
             to treat the patient's malignancy&#xD;
&#xD;
          -  No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy, surgery for&#xD;
             cancer, or experimental medications&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wong Nan Soon, MBBS, MRCP, FAMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wong Chow Yin</last_name>
      <phone>65-6222-3322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wong Nan Soon, MBBS, MRCP, FAMS</last_name>
      <phone>65-6-436-8088</phone>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>June 16, 2009</last_update_submitted>
  <last_update_submitted_qc>June 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2009</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

